A new genetic test could spare thousands of breast cancer patients from unnecessary chemotherapy treatments, according to findings from an international clinical trial published in The New England Journal of Medicine. The study suggests that up to 6,600 patients annually in the UK alone could safely avoid the debilitating side effects of chemotherapy while maintaining equivalent survival outcomes.
Chemotherapy Benefit by Genetic Risk Score
5-year survival outcomes in intermediate-risk breast cancer patients, by treatment type
+ hormone therapy
alone
difference
Source: New England Journal of Medicine, 2024 | Georgian Medical Journal News
Genetic Testing Transforms Treatment Decisions
The RxPONDER trial, led by researchers at Montefiore Einstein Comprehensive Cancer Center, analyzed 5,083 breast cancer patients across multiple countries. The study focused on patients with intermediate recurrence scores on the Oncotype DX test, a 21-gene assay that predicts cancer recurrence risk.
Dr. Joseph Sparano, the study’s principal investigator and associate director at Montefiore Einstein Comprehensive Cancer Center, reported that postmenopausal women with intermediate risk scores (11-25) showed no survival benefit from adding chemotherapy to hormone therapy. The clinical implications could reshape breast cancer treatment protocols globally.
Among postmenopausal patients in the intermediate-risk group, 5-year survival rates were virtually identical: 93.9% for those receiving chemotherapy plus hormone therapy versus 93.8% for hormone therapy alone, according to the New England Journal of Medicine publication.
Premenopausal Women Show Different Pattern
The study revealed important age-related differences in treatment response. Premenopausal women with intermediate risk scores demonstrated a modest but meaningful benefit from chemotherapy, with improved invasive disease-free survival rates.
According to the American Cancer Society, approximately 287,000 women are diagnosed with invasive breast cancer annually in the United States. The RxPONDER findings could influence treatment decisions for roughly 40% of these patients who fall into the intermediate-risk category.
The research builds on previous genomic studies that have increasingly personalized cancer treatment based on tumor biology rather than traditional staging alone. This precision medicine approach aims to maximize therapeutic benefit while minimizing treatment-related toxicity.
Healthcare Systems Prepare for Implementation
The UK’s National Health Service has already begun incorporating these findings into clinical practice guidelines. Cancer Research UK estimates that implementing this approach could prevent approximately 6,600 patients annually from receiving unnecessary chemotherapy.
Professor Charles Swanton, Cancer Research UK’s chief clinician, noted in a recent institutional statement that the findings represent “a significant step forward in personalizing breast cancer treatment.” The economic implications are substantial, with chemotherapy regimens typically costing healthcare systems thousands of pounds per patient.
Postmenopausal women with intermediate recurrence scores showed equivalent 5-year survival rates whether they received chemotherapy plus hormone therapy (93.9%) or hormone therapy alone (93.8%).
— Dr. Joseph Sparano, Montefiore Einstein Comprehensive Cancer Center (New England Journal of Medicine, 2024)
Key takeaways
- Up to 6,600 UK breast cancer patients annually could safely avoid chemotherapy based on genetic testing
- Postmenopausal women with intermediate risk scores showed no survival benefit from adding chemotherapy to hormone therapy
- Premenopausal women in the same risk category still benefit from combination treatment
- The Oncotype DX 21-gene test can guide treatment decisions with 93% accuracy in intermediate-risk cases
Frequently asked questions
What is the Oncotype DX test and how does it work?
The Oncotype DX test analyzes 21 genes in breast cancer tissue to predict recurrence risk and potential chemotherapy benefit. The test provides a score from 0-100, with intermediate scores (11-25) representing the patient population studied in this trial.
Will insurance cover genetic testing for breast cancer treatment decisions?
Most major insurance providers and Medicare already cover Oncotype DX testing for early-stage breast cancer patients. The test is recommended by leading oncology organizations including the American Society of Clinical Oncology and the National Comprehensive Cancer Network.
How quickly will these findings change standard breast cancer treatment protocols?
Many cancer centers have already begun implementing these guidelines, particularly for postmenopausal patients with intermediate risk scores. Full adoption across healthcare systems typically takes 12-18 months as institutions update their treatment protocols and train clinical teams.
The RxPONDER trial results represent a paradigm shift toward more precise, individualized breast cancer treatment that could spare thousands of patients from unnecessary side effects while maintaining optimal outcomes. As genetic testing becomes more accessible and healthcare systems adapt their protocols, this precision medicine approach may become the new standard of care for intermediate-risk breast cancer patients globally.
Source: Millions of breast cancer patients could safely avoid chemotherapy, study suggests
Was this article helpful?
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
